Please select the option that best describes you:

In patients with Philadelphia-negative ALL who are transplant ineligible, is there any data to guide the duration of maintenance POMP therapy?  

Does your approach change if the MRD is negative post-blinatumomab?



Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more